Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial
Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) today announced detailed positive results from the Phase 3 NIMBLE trial evaluating investigational cemdisiran in a
Description
Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) today announced detailed positive results from the Phase 3 NIMBLE trial evaluating investigational cemdisiran in a
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source